BIS: Retail gold purchases have tripled in the past six months, while institutional selling has accelerated.
PANews March 19 news, according to Cointelegraph, data from the Bank for International Settlements (BIS) shows that retail investors' gold purchases have doubled over the past six months, while institutional investors have accelerated their sell-offs during the same period. Since the second quarter of 2025, retail investors have bought approximately $70 billions worth of gold ETFs, with purchases in the past six months more than doubling. Institutional sell-offs began in mid-November last year and accelerated after the precious metals market started to correct in January.
The BIS report points out that retail inflows into ETFs and leveraged positions have driven the rise in precious metals, but daily rebalancing of leveraged ETFs and margin-triggered liquidations have amplified price volatility, especially in the silver market. Gold prices have fallen 9% from the historical high at the end of January, while silver has plummeted 34% over the same period. BIS stated that the decline in precious metals coincided with changes in market expectations for U.S. monetary policy and the performance of the dollar, but it is difficult to match these moves with fundamental changes. Meanwhile, the total market capitalization of the crypto market has dropped about 43% from its peak in October.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
